Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions ...
Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic ...
Enzalutamide Plus Leuprolide Extends Treatment Suspension in Biochemically Recurrent Prostate Cancer
An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...
A skincare expert uncovers the truths and debunks the myths surrounding retinol, plus our top retinol picks including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results